Your browser doesn't support javascript.
loading
[Sequential infusion of anti-CD22 and anti-CD19 CAR-T cells in the treatment of relapsed / refractory childhood acute B lymphoblastic leukemia: two cases report].
Zhang, J; Wu, X X; Li, M Y; Song, B Q; Zhou, L L; Kong, X; Qiu, H Y; Wu, D P.
Afiliación
  • Zhang J; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Hematology Department, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, Suzhou 215006, China.
  • Wu XX; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Hematology Department, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, Suzhou 215006, China.
  • Li MY; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Hematology Department, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, Suzhou 215006, China.
  • Song BQ; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Hematology Department, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, Suzhou 215006, China.
  • Zhou LL; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Hematology Department, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, Suzhou 215006, China.
  • Kong X; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Hematology Department, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, Suzhou 215006, China.
  • Qiu HY; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Hematology Department, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, Suzhou 215006, China.
  • Wu DP; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Hematology Department, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, Suzhou 215006, China.
Zhonghua Xue Ye Xue Za Zhi ; 43(3): 258, 2022 03 14.
Article en Zh | MEDLINE | ID: mdl-35405786
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígenos CD19 / Leucemia-Linfoma Linfoblástico de Células Precursoras Límite: Child / Humans Idioma: Zh Revista: Zhonghua Xue Ye Xue Za Zhi Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antígenos CD19 / Leucemia-Linfoma Linfoblástico de Células Precursoras Límite: Child / Humans Idioma: Zh Revista: Zhonghua Xue Ye Xue Za Zhi Año: 2022 Tipo del documento: Article País de afiliación: China